Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18763262 | SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | July 2024 | February 2025 | Allow | 8 | 0 | 0 | Yes | No |
| 18381272 | 3-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18451243 | IMMUNOMODULATING UREA AZALIDES | August 2023 | March 2025 | Allow | 19 | 1 | 0 | No | No |
| 18450646 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | August 2023 | March 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18190407 | MESCALINE DERIVATIVES WITH MODIFIED ACTION | March 2023 | May 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18070374 | MESCALINE DERIVATIVES WITH MODIFIED ACTION | November 2022 | May 2025 | Abandon | 30 | 0 | 1 | No | No |
| 18047454 | MULTI-ARM SINGLE MOLECULAR WEIGHT POLYETHYLENE GLYCOL ACTIVE DERIVATIVE AND APPLICATION THEREOF | October 2022 | April 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 17930015 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | September 2022 | May 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17929777 | IMMUNOMODULATING AZALIDES | September 2022 | March 2025 | Allow | 31 | 2 | 0 | No | No |
| 17908530 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | August 2022 | June 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17887776 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | August 2022 | April 2025 | Allow | 32 | 1 | 0 | No | No |
| 17871458 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | July 2022 | March 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17849600 | SMALL MOLECULE COMPOUNDS | June 2022 | November 2023 | Abandon | 16 | 1 | 1 | No | No |
| 17841138 | CDK2/4/6 Inhibitors | June 2022 | July 2024 | Allow | 25 | 0 | 0 | Yes | No |
| 17739737 | SPIROBIFLUORENE COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | May 2022 | February 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17755167 | Nitrogen-containing Derivative of Substituted Phenol Hydroxy Acid Ester, and Preparation and Use Thereof | April 2022 | March 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17767276 | Na/K-ATPase LIGANDS AND USE THEREOF FOR TREATMENT OF CANCER | April 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17767188 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | April 2022 | April 2025 | Allow | 36 | 0 | 1 | Yes | No |
| 17705624 | RUXOLITINIB FORMULATION FOR REDUCTION OF ITCH IN ATOPIC DERMATITIS | March 2022 | September 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17702894 | CRYSTALLINE POLYMORPHS OF 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17698719 | APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17697247 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17676169 | MESCALINE DERIVATIVES WITH MODIFIED ACTION | February 2022 | January 2025 | Abandon | 35 | 3 | 0 | No | No |
| 17666692 | BENZYLAMINO-OXOETHYL BENZAMIDE ANALOGS AND METHODS OF USE | February 2022 | January 2024 | Allow | 24 | 0 | 0 | No | No |
| 17579150 | NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE | January 2022 | November 2024 | Allow | 34 | 1 | 1 | No | No |
| 17570299 | SALTS AND SOLID FORMS OF (S)-3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | January 2022 | August 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17623772 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS | December 2021 | September 2022 | Allow | 8 | 1 | 0 | No | No |
| 17623356 | ORGANIC COMPOUND, ELECTRONIC COMPONENT CONTAINING ORGANIC COMPOUND, AND ELECTRONIC DEVICE | December 2021 | September 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17560545 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | December 2021 | December 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17554725 | PHOTOPROTECTIVE COMPOSITIONS CONTAINING MALASSEZIA-DERIVED COMPOUNDS AND/OR CHEMICAL ANALOGS THEREOF | December 2021 | June 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17614100 | GPR40 AGONISTS | November 2021 | April 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17534348 | FORMULATIONS AND METHODS FOR TREATING CONDITIONS OF THE EYE | November 2021 | June 2024 | Abandon | 31 | 0 | 1 | No | No |
| 17523160 | ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBROVASCULAR DISEASE | November 2021 | April 2025 | Allow | 41 | 3 | 1 | No | No |
| 17519239 | SYNTHESIS OF CRAC CHANNEL INHIBITORS | November 2021 | December 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17517060 | COMPOSITION, PHOTOELECTRIC CONVERSION ELEMENT, AND IMAGING DEVICE | November 2021 | February 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17606884 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | October 2021 | April 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17594575 | NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA | October 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17505699 | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | October 2021 | December 2024 | Abandon | 38 | 3 | 1 | Yes | No |
| 17500625 | Methods of Treating IgA Nephropathy with Thiol-Containing Molecules | October 2021 | December 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17496568 | SYSTEM AND METHOD FOR REACTING ONE OR MORE COMPOUNDS TO FORM TETRAHYDROCANNABINOLIC ACID (THCA) | October 2021 | May 2024 | Allow | 31 | 2 | 0 | Yes | No |
| 17601487 | PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS | October 2021 | July 2022 | Allow | 10 | 1 | 0 | Yes | No |
| 17484420 | Mechanosynthesis of a Co-Amorphous Formulation of Creatine with Citric Acid and Humidity-Mediated Transformation into a Co-Crystal | September 2021 | November 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17475486 | WATER-SOLUBLE YNAMIDE COUPLING REAGENT AND PREPARATION METHOD AND USE THEREOF | September 2021 | September 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17403964 | MODIFIED PEG-400 - ASCORBIC ACID (mPEG-AA) COMPLEX AND USES THEREOF | August 2021 | January 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17400820 | BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS | August 2021 | April 2025 | Abandon | 44 | 2 | 0 | Yes | No |
| 17382591 | METHOD FOR THE INDUSTRIAL PRODUCTION OF 2-HALO-4,6-DIALKOXY-1,3,5-TRIAZINES AND THEIR USE IN THE PRESENCE OF AMINES | July 2021 | September 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17424071 | METAL COMPOUND HAVING PHASE TRANSFORMATION AND METHOD OF PREPARING THE SAME | July 2021 | May 2022 | Allow | 10 | 1 | 0 | Yes | No |
| 17378960 | Hydroxide-Catalyzed Formation Of Silicon-Oxygen Bonds By Dehydrogenative Coupling Of Hydrosilanes And Alcohols | July 2021 | June 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17310092 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17366313 | Pharmaceutical composition and use thereof | July 2021 | June 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17363770 | PRODUCTION OF NITROGEN-CONTAINING CHELATORS | June 2021 | February 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17312557 | Pharmaceutical composition and use thereof | June 2021 | December 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17312658 | Crystalline Forms and Salt Forms of a Kinase Inhibitor | June 2021 | April 2024 | Allow | 35 | 1 | 0 | No | No |
| 17311669 | USE OF A BERBERIS AND RESVERATROL MIXTURE TO CONTROL DYSLIPIDEMIA | June 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17311634 | PHARMACEUTICAL COMPOSITIONS OF FUROSEMIDE AND USES THEREOF | June 2021 | April 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17338643 | ETHYNYL DERIVATIVES | June 2021 | September 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17291099 | O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD | June 2021 | January 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17298652 | PANTETHEINE DERIVATIVES AND USES THEREOF | May 2021 | March 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17298281 | FEED ADDITIVE COMPOSITION AND FEED COMPOSITION COMPRISING THE SAME | May 2021 | February 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17315538 | POLYMORPHS | May 2021 | June 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17291042 | MIXTURES AND COMPOSITIONS COMPRISING 5-FLUORO-4-IMINO-3-METHYL-1-TOSYL-3,4-DIHYDROPYRIMIDIN-2-ONE, AND METHODS OF USE THEREOF | May 2021 | May 2025 | Allow | 48 | 1 | 1 | No | No |
| 17306617 | PROCESS FOR THE PREPARATION OF RIVAROXABAN INVOLVING NOVEL INTERMEDIATE | May 2021 | October 2023 | Allow | 29 | 0 | 0 | Yes | No |
| 17236745 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | April 2021 | May 2022 | Allow | 12 | 1 | 1 | Yes | No |
| 17236008 | ORAL DISSOLVABLE FILM WITH HIGH LOAD OF POLYMERIC BINDER | April 2021 | April 2025 | Abandon | 47 | 3 | 1 | No | No |
| 17232015 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | April 2021 | October 2023 | Allow | 30 | 0 | 0 | Yes | No |
| 17221000 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof | April 2021 | July 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17278890 | DEGRADERS OF WEE1 KINASE | March 2021 | January 2025 | Allow | 46 | 1 | 1 | No | No |
| 17201827 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | March 2021 | December 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17201268 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | March 2021 | April 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17199999 | USE OF C3aR IN PREPARING DRUG FOR PREVENTING OR TREATING POLYCYSTIC KIDNEY DISEASE | March 2021 | May 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17198863 | IMMUNOMODULATING UREA AZALIDES | March 2021 | August 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17192609 | IP AND IP ANALOGS DOSAGE REGIMENS FOR THE TREATMENT OF ECTOPIC CALCIFICATIONS | March 2021 | April 2024 | Allow | 38 | 2 | 1 | No | No |
| 17192569 | SONODYNAMIC THERAPY USING SONODYNAMICALLY ACTIVATED COORDINATION COMPLEXES OF TRANSITION METALS AS SENSITIZING AGENTS | March 2021 | July 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17188422 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | March 2021 | July 2024 | Abandon | 40 | 1 | 1 | No | No |
| 17179801 | Methods of Using Androgen Receptor Inhibitors as Cancer Therapeutics | February 2021 | February 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17169611 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | February 2021 | November 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17164446 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | February 2021 | March 2024 | Allow | 37 | 1 | 1 | No | No |
| 17264394 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | January 2021 | November 2022 | Allow | 21 | 0 | 0 | No | No |
| 17162614 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | January 2021 | April 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17146850 | COMPOUND AND PHOTOELECTRIC DEVICE, IMAGE SENSOR, AND ELECTRONIC DEVICE INCLUDING THE SAME | January 2021 | September 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17132580 | Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory Disorders | December 2020 | May 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17132773 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | December 2020 | March 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17254962 | FORMULATIONS COMPRISING DOPAMINE-B-HYDROXYLASE INHIBITORS AND METHODS FOR THEIR PREPARATION | December 2020 | March 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17127297 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | December 2020 | July 2023 | Allow | 30 | 1 | 1 | Yes | No |
| 17122726 | PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS | December 2020 | April 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17251070 | 2-NAPHTHIMIDAMIDES, ANALOGUES THEREOF, AND METHODS OF TREATMENT USING SAME | December 2020 | January 2023 | Allow | 25 | 1 | 0 | No | No |
| 16972660 | INHIBITORS OF SARM1 | December 2020 | June 2025 | Allow | 54 | 3 | 1 | Yes | No |
| 17108227 | Combining BACE1 Inhibitors With mGluR Agonists For Alzheimer's Disease Therapy | December 2020 | July 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17057297 | NOVEL HIF-1ALPHA INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | November 2020 | December 2023 | Allow | 37 | 3 | 1 | No | No |
| 16953201 | BENZATHINE ANALOGS | November 2020 | August 2023 | Allow | 33 | 0 | 0 | Yes | No |
| 16950542 | PROCESS FOR THE SYNTHESIS OF (S) 3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID | November 2020 | July 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 17097913 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17055190 | SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES | November 2020 | February 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17096439 | Inhibitors of Mcl-1 and Akt Binding, Pharmaceutical Compositions, and Uses in Treating Cancer | November 2020 | December 2023 | Abandon | 37 | 2 | 0 | No | No |
| 17086963 | EXTENDED RELEASE L-TRI-IODOTHYRONINE AMELIORATES THE PATHOPHYSIOLOGY OF THE MATERNAL PRE-ECLAMPSIA SYNDROME | November 2020 | April 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17086913 | Treatment for Tau-Related Diseases | November 2020 | June 2025 | Allow | 55 | 7 | 0 | Yes | No |
| 17080516 | PROCESS FOR THE PREPARATION OF A SUBSTITUTED IMIDAZOTHIAZOLONE COMPOUND | October 2020 | November 2024 | Abandon | 49 | 3 | 0 | No | No |
| 17070271 | USE OF SUBSTITUTED AMINOPROPIONATE COMPOUNDS IN TREATMENT OF SARS-COV-2 INFECTION | October 2020 | June 2024 | Abandon | 44 | 3 | 0 | No | No |
| 17068574 | TDO2 Inhibitors | October 2020 | June 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 17065463 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PATEL, SAGAR S.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PATEL, SAGAR S works in Art Unit 1626 and has examined 548 patent applications in our dataset. With an allowance rate of 72.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner PATEL, SAGAR S's allowance rate of 72.6% places them in the 28% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by PATEL, SAGAR S receive 1.36 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by PATEL, SAGAR S is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +37.8% benefit to allowance rate for applications examined by PATEL, SAGAR S. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.8% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 38.2% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 64.3% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 49% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.0% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.